About Event

The 3rd Lipid Nanoparticles Development Summit Europe was a leading forum to unite a driven community of leaders, forcing lipid nanoparticle innovative design and manufacture into the centre of the conversation, demanding more clinical progress and regulatory approval across a wide range of payloads. The spotlight was on the challenges impacting discovery, formulation, characterization and manufacturing teams across Europe and beyond in a bid to create novel lipid nanoparticles.

With an agenda developed following consultative discussion with the field’s biggest players, GSK, J&J, CureVac and more, this summit was of highest value for the community to receive end-to-end LNP insights. Development roadblocks such as lipid characterisation, model translatability, toxicity occurrence, targeted delivery formed core parts of the discussion, delivered from world-leading speakers across pharma, biotech and academia.